Literature DB >> 13944597

Non-toxic goiter treatment with 1-triiodothyronine and 1-thyroxine.

W N FAWELL, B CATZ.   

Abstract

Twenty-one patients with goiters-four diffuse and 17 nodular-were treated with I-triiodothyronine and I-thyroxine in doses to tolerance. The four diffuse goiters were barely palpable at the end of the treatment. The average dose of I-triiodothyronine required was 100 mcg. per day. The average dose of I-thyroxine was 0.3 mg. per day. Of the 17 multinodular goiters, 11 showed at least a 50 per cent reduction in size. The average dose of I-triiodothyronine used was 125 mcg. In six cases the gland did not change in size; in three of the six the lesion was diagnosed, at operation, as microfollicular and macrofollicular colloid goiter. Hypermetabolic symptoms may occur when doses of 100 mcg. or more of I-triiodothyronine are used. Results indicated that suppressive therapy with thyroid hormone to tolerance is effective in diffuse goiters. It is only partially effective in the treatment of multinodular goiters. In the cases in which operation was done, no change in the basic histological goiter structure was observed.

Entities:  

Keywords:  GOITER; THYROXIN; TRIIODOTHYRONINE

Mesh:

Substances:

Year:  1963        PMID: 13944597      PMCID: PMC1575601     

Source DB:  PubMed          Journal:  Calif Med        ISSN: 0008-1264


  4 in total

1.  Triiodothyronine in myxedema and familial sporadic cretinism with goiter.

Authors:  H ZONDEK; H E LESZYNSKY; G W ZONDEK
Journal:  Acta Endocrinol (Copenh)       Date:  1955-02

2.  Treatment of non-toxic goitre with thyroid preparations.

Authors:  B A LAMBERG; C A HERNBERG; R HAKKILA
Journal:  Acta Endocrinol (Copenh)       Date:  1960-04

3.  Use of triiodothyronine for reduction of goiter and detection of thyroid cancer.

Authors:  P STARR; W GOODWIN
Journal:  Metabolism       Date:  1958-07       Impact factor: 8.694

4.  Treatment of simple goiter with thyroid.

Authors:  M A GREER; E B ASTWOOD
Journal:  J Clin Endocrinol Metab       Date:  1953-11       Impact factor: 5.958

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.